Please try another search
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. The Company’s pipeline is focused on three core areas: CAR T therapies for hematologic malignancies, CAR T therapies for solid tumors, and gene therapies for rare genetic disorders. The Company is developing CAR T therapies for hematologic malignancies in partnership with the City of Hope National Medical Center (COH) targeting CD123 (MB-102) and CS1 (MB-104) and with Fred Hutchinson Cancer Center (Fred Hutch) targeting CD20 (MB-106). It is also developing CAR T therapies for solid tumors in partnership with COH targeting IL13Ra2 (MB-101), HER2 (MB-103), and PSCA (MB-105).
Name | Age | Since | Title |
---|---|---|---|
Michael J. Zelefsky | 61 | 2017 | Independent Director |
Lindsay Allan Rosenwald | 66 | 2015 | Non-Executive Director |
Adam J. Chill | 53 | 2017 | Independent Director |
Neil Herskowitz | 64 | 2015 | Independent & Non-Executive Director |
Michael S. Weiss | 57 | 2015 | Executive Chairman |
Manuel Litchman | 70 | 2017 | President, CEO & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review